Advertisement
Organisation › Details
AdBio Partners (Group)
AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences – specifically in therapeutics-oriented projects. Its unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio partners has made 22 European investments in France, Belgium, Spain and Ireland – with two funds: AFB Seed Fund I and AFB FII. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team includes investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise. *AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. *
Start | 2021-12-07 renamed | |
Predecessor | Advent France Biotechnology SAS (AFB) | |
Industry | venture capital | |
Industry 2 | BIOTECH | |
Person | Coutet, Matthieu (Advent France Biotechnology 201704 Managing Partner before Inserm Transfert) | |
Person 2 | Huriez, Alain (Advent France Biotechnology 201704 Managing Partner before Advent Life Sciences + TcLand + Neovacs) | |
Region | Paris | |
Country | France | |
Street | 4 rue Thénard | |
City | 75005 Paris | |
Tel | +33-1-5681-6300 | |
Address record changed: 2024-09-07 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: DiogenX SAS. (5/10/23). "Press Release: DiogenX Raises €27.5M Series A Financing to Advance Its First-in-Class Regenerative Treatment for Type 1 Diabetes Towards Clinical Development". Marseille. | ||
Record changed: 2024-09-07 |
Advertisement
More documents for AdBio Partners (Group)
- [1] AdBio Partners SAS. (6/18/24). "Press Release: Inserm Transfert and AdBio Partners Launch AndzonBio". Paris....
- [2] AdBio Partners SAS. (6/4/24). "Press Release: AdBio Partners Promotes Emma Gasol to Partner". Paris & Barcelona....
- [3] AdBio Partners SAS. (10/16/23). "Press Release: AdBio Partners Continues to Strengthen Its Senior Investment Team with Emma Gasol as Director of Investments". Paris & Barcelona....
- [4] AdBio Partners SAS. (9/4/23). "Press Release: AdBio Partners Appoints Laurence de Schoulepnikoff as Venture Partner". Paris....
- [5] AdBio Partners SAS. (7/11/23). "Press Release: AdBio Partners Strengthens Its Management Team and Promotes Clément Bertholet as Partner". Paris....
- [6] Astraveus SAS. (6/27/23). "Press Release: Astraveus Raises €16.5 Million Series Seed Round to Advance the Development of Its Automated, Microfluidic Cell and Gene Therapy Manufacturing Platform". Paris....
- [7] Calida Therapeutics SAS. (4/6/23). "Press Release: French Biotech Calida Therapeutics Launches with Seed Funding, Leveraging US Academic Research in Thrombo-inflammatory Disorders". Paris....
- [8] AdBio Partners SAS. (2/23/23). "Press Release: AdBio Partners Appoints Geoffroy de Ribains as Managing Partner". Paris....
- [9] Thabor Therapeutics SAS. (5/17/22). "Press Release: Thabor Therapeutics Appoints Jérémie Mariau as CEO". Paris....
- [10] AdBio Partners SAS. (5/3/22). "Press Release: AdBio Partners Welcomes Inserm Transfert as Investor in Second Fund – AFB Fund II". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top